HFM
CORT icon

Harvest Fund Management’s Corcept Therapeutics CORT Stock Holding History

Harvest Fund Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-827
Closed -$69K – 612
2025
Q3 		$69K Buy
+827
New +$59.8K ﹤0.01% 417
2025
Q1 		– Sell
-1,362
Closed -$61K – 703
2024
Q4 		$61K Buy
+1,362
New +$71.4K ﹤0.01% 588
2017
Q4 		– Sell
-2,759
Closed -$53K – 226
2017
Q3 		$53K Buy
+2,759
New +$41.1K 0.01% 145

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Harvest Fund Management's CORT Position: Q4 2025 in Review

Harvest Fund Management sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 827 shares — an estimated $69K sold.

Harvest Fund Management first reported a position in CORT in Q3 2017 and held it in 3 quarters. The position peaked at $69K in Q3 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

  • Harvest Fund Management reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Harvest Fund Management sold 827 Corcept Therapeutics shares in Q4 2025, an estimated $69K.
  • Harvest Fund Management first reported a position in Corcept Therapeutics in Q3 2017 and held it in 3 quarters.
  • Harvest Fund Management's Corcept Therapeutics position peaked at $69K in Q3 2025.
  • 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on Harvest Fund Management's 13F filing for Q4 2025, filed 11 Feb 2026.